18F-DCFPyL PET-CT对退伍军人侵袭性前列腺癌初始分期及放化疗推荐的影响
一项单中心单臂前瞻性成像试验纳入100例未治疗的高危前列腺癌退伍军人,在常规影像基础上加做18F-DCFPyL PET-CT。结果显示23%的非转移患者被上调为M1,50%的M1患者被下调为M0,39%的患者预设治疗推荐发生改变。
要点
- 18F-DCFPyL PET-CT使23%初始非转移患者上调为M1。
- 50%初始M1患者被下调为M0。
- 39%患者预设治疗推荐改变,包括放疗体积/剂量和开始阿比特龙。
核心结论
- 将18F-DCFPyL PET-CT纳入前列腺癌初始常规影像检查可显著影响分期和治疗推荐。
研究设计与样本
- 前瞻性单中心单臂成像试验,纳入100例符合Gleason≥4+3、临床分期≥T2c或PSA>10 ng/mL的退伍军人。
主要发现
- 16例初始M1患者中8例(50%)下调为M0。
- 39/100(39%)患者预设治疗推荐改变,其中放疗体积/剂量改变39/100(39%),开始阿比特龙22/100(22%)。
临床怎么用
- 对高危前列腺癌退伍军人,在常规影像基础上加做18F-DCFPyL PET-CT可辅助更准确分期并调整放疗或系统治疗推荐。
局限性
- 单中心单臂设计,样本量100例,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to study the effect of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography (PET)-computed tomography (CT) on staging/treatment recommendations of previously untreated prostate cancer. We report here results of a prospective single center single arm imaging trial within Veterans Affairs (Greater Los Angeles): the frequency of patients upstaged to M1 disease (primary endpoint) and the frequency of patients with change in treatment recommendations (secondary endpoint). This is the first report of prostate-specific membrane antigen PET-CT exclusive to U.S. veterans. METHODS AND MATERIALS: Veterans with Gleason ≥4 + 3, clinical stage ≥T2c, or prostate-specific antigen >10 ng/mL were eligible. Patients underwent conventional imaging (99mTc-methyl diphosphonate bone scan or 18F-NaF PET-CT; and pelvic CT or pelvic magnetic resonance imaging) in addition to 18F-DCFPyL PET-CT. The effect of 18F-DCFPyL PET-CT on treatment change was determined by applying prespecified treatment recommendations based on National Comprehensive Cancer Network guidelines and modern clinical practice. RESULTS: One hundred patients underwent 18F-DCFPyL PET-CT. Nineteen out of 84 (23%) patients initially thought to be nonmetastatic were upstaged to M1; 8/16 (50%) patients initially thought to have M1 disease were downstaged to M0. In total, 39/100 (39%) had a change in prespecified treatment recommendations, including change of radiation therapy volume/dose in 39/100 (39%) and starting abiraterone in 22/100 (22%). CONCLUSIONS: Incorporation of 18F-DCFPyL PET-CT into the initial conventional imaging workup for prostate cancer can substantially affect staging/treatment recommendations.
引用
- Parikh NR, Tsai S, Bennett C, et al. The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020. PMID: 33305100. doi:10.1016/j.adro.2020.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。